Premium
HLA and β 2 ‐microglobulin Expression in Basal and Squamous Cell Carcinomas of the Skin
Author(s) -
Hua Lin Al,
Kagen Charles N.,
Carpenter Randall J.,
Goltz Robert W.
Publication year - 1985
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1985.tb05719.x
Subject(s) - immunoperoxidase , beta 2 microglobulin , antigen , human leukocyte antigen , pathology , cell , monoclonal antibody , polyclonal antibodies , medicine , antibody , cancer research , biology , immunology , genetics
Histologic sections of seven sequamous cell carcinomas (SCC), 13 basal cell carcinomas (BCC), and a bowenoid actinic keratoses were examined for expression of HLA class 1 antigens (HLA‐ABC) using a monoclonal antibody and an immunoperoxidase technique. Expression of β 2 ‐microglobulin was examined with a polyclonal antibody method. Neither cell marker was detected within the Bowwenoid actinic keratoses. Squamous cell carcinomas and basla cell carcinomas exhibited decreased expression of both HLA‐ABC and β 2 ‐microglobulin and often did not express these antigens at all. HLA‐ABC was present in only two of 13 basal cell carcinomas and four of seven sequamous cell carcinomas. β 2 ‐microglobulin was present in one of 13 basal cell carcinomas and two of seven squamous cell carcinomas. When present, these antigens other. In both SCC and BCC, both antigens were usually lost simultaneously. In all tumors with β 2 ‐microglobulin, HLA‐ABC and β 2 ‐microglobulin on their surfaces, the absence of these antigens is not an absolute marker for malignanancy.